Clinical Trial Update: The Efficacy and Safety of Sintilimab Plus Chemotherapy in Surgical Conversion for Patients With Unresectable Stage IIIB-IIIC NSCLC: A Prospective, Single-Arm, Phase II Study [Phase 2]

View source ↗

Summary

A Phase II, single-arm study evaluating sintilimab plus chemotherapy for converting unresectable stage IIIB-IIIC non-small cell lung cancer to resectable diseas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Chemotherapy (chemotherapy)
• Sintilimab (sintilimab)

Snippet

Sponsor: Zhejiang University | Conditions: Non Small Cell Lung Cancer (Stage III) | Phase 2 | Status: NOT_YET_RECRUITING